Hemostemix Stock Total Debt
| HEM Stock | CAD 0.08 0.01 5.88% |
Hemostemix fundamentals help investors to digest information that contributes to Hemostemix's financial success or failures. It also enables traders to predict the movement of Hemostemix Stock. The fundamental analysis module provides a way to measure Hemostemix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hemostemix stock.
Total Debt To Capitalization is likely to drop to -1.49 in 2024. Hemostemix | Total Debt |
Hemostemix Company Total Debt Analysis
Hemostemix's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Hemostemix Total Debt | 4.32 M |
Most of Hemostemix's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemostemix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Hemostemix Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Hemostemix is extremely important. It helps to project a fair market value of Hemostemix Stock properly, considering its historical fundamentals such as Total Debt. Since Hemostemix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Hemostemix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Hemostemix's interrelated accounts and indicators.
Click cells to compare fundamentals
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Hemostemix Net Debt
Net Debt |
|
Based on the latest financial disclosure, Hemostemix has a Total Debt of 4.32 M. This is 99.84% lower than that of the Biotechnology sector and 98.67% lower than that of the Health Care industry. The total debt for all Canada stocks is 99.92% higher than that of the company.
Hemostemix Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hemostemix's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hemostemix could also be used in its relative valuation, which is a method of valuing Hemostemix by comparing valuation metrics of similar companies.Hemostemix is currently under evaluation in total debt category among its peers.
Hemostemix Fundamentals
| Return On Asset | -3.49 | ||||
| Current Valuation | 14.43 M | ||||
| Shares Outstanding | 123.98 M | ||||
| Shares Owned By Insiders | 9.54 % | ||||
| Number Of Shares Shorted | 11.93 K | ||||
| Price To Earning | (1.70) X | ||||
| Price To Book | 27.76 X | ||||
| EBITDA | (2.16 M) | ||||
| Net Income | (2.5 M) | ||||
| Cash And Equivalents | 49.36 K | ||||
| Total Debt | 4.32 M | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.1) X | ||||
| Cash Flow From Operations | (1.5 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 0.96 | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 9.92 M | ||||
| Total Asset | 313.76 K | ||||
| Retained Earnings | (63.27 M) | ||||
| Working Capital | (2.56 M) | ||||
| Net Asset | 313.76 K |
About Hemostemix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hemostemix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hemostemix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hemostemix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.